TY - JOUR
T1 - Epitranscriptomics of Ischemic Heart Disease—The IHD-EPITRAN Study Design and Objectives
AU - Sikorski, Vilbert
AU - Karjalainen, Pasi
AU - Blokhina, Daria
AU - Oksaharju, Kati
AU - Khan, Jahangir
AU - Katayama, Shintaro
AU - Rajala, Helena
AU - Suihko, Satu
AU - Tuohinen, Suvi Sirkku
AU - Teittinen, Kari
AU - Nummi, Annu
AU - Nykänen, Antti
AU - Eskin, Arda
AU - Stark, Christoffer
AU - Biancari, Fausto
AU - Kiss, Jan
AU - Simpanen, Jarmo
AU - Ropponen, Jussi O
AU - Lemström, Karl
AU - Savinainen, Kimmo
AU - Lalowski, Maciej
AU - Kaarne, Markku
AU - Jormalainen, Mikko
AU - Elomaa, Outi
AU - Koivisto, Pertti
AU - Raivio, Peter
AU - Bäckström, Pia
AU - Dahlbacka, Sebastian
AU - Syrjälä, Simo
AU - Vainikka, Tiina
AU - Vähäsilta, Tommi
AU - Tuncbag, Nurcan
AU - Karelson, Mati
AU - Mervaala, Eero
AU - Juvonen, Tatu
AU - Laine, Mika
AU - Laurikka, Jari
AU - Vento, Antti
AU - Kankuri, Esko
PY - 2021/6/21
Y1 - 2021/6/21
N2 - Epitranscriptomic modifications in RNA can dramatically alter the way our genetic code is deciphered. Cells utilize these modifications not only to maintain physiological processes, but also to respond to extracellular cues and various stressors. Most often, adenosine residues in RNA are targeted, and result in modifications including methylation and deamination. Such modified residues as N-6-methyl-adenosine (m6A) and inosine, respectively, have been associated with cardiovascular diseases, and contribute to disease pathologies. The Ischemic Heart Disease Epitranscriptomics and Biomarkers (IHD-EPITRAN) study aims to provide a more comprehensive understanding to their nature and role in cardiovascular pathology. The study hypothesis is that pathological features of IHD are mirrored in the blood epitranscriptome. The IHD-EPITRAN study focuses on m6A and A-to-I modifications of RNA. Patients are recruited from four cohorts: (I) patients with IHD and myocardial infarction undergoing urgent revascularization; (II) patients with stable IHD undergoing coronary artery bypass grafting; (III) controls without coronary obstructions undergoing valve replacement due to aortic stenosis and (IV) controls with healthy coronaries verified by computed tomography. The abundance and distribution of m6A and A-to-I modifications in blood RNA are charted by quantitative and qualitative methods. Selected other modified nucleosides as well as IHD candidate protein and metabolic biomarkers are measured for reference. The results of the IHD-EPITRAN study can be expected to enable identification of epitranscriptomic IHD biomarker candidates and potential drug targets.
AB - Epitranscriptomic modifications in RNA can dramatically alter the way our genetic code is deciphered. Cells utilize these modifications not only to maintain physiological processes, but also to respond to extracellular cues and various stressors. Most often, adenosine residues in RNA are targeted, and result in modifications including methylation and deamination. Such modified residues as N-6-methyl-adenosine (m6A) and inosine, respectively, have been associated with cardiovascular diseases, and contribute to disease pathologies. The Ischemic Heart Disease Epitranscriptomics and Biomarkers (IHD-EPITRAN) study aims to provide a more comprehensive understanding to their nature and role in cardiovascular pathology. The study hypothesis is that pathological features of IHD are mirrored in the blood epitranscriptome. The IHD-EPITRAN study focuses on m6A and A-to-I modifications of RNA. Patients are recruited from four cohorts: (I) patients with IHD and myocardial infarction undergoing urgent revascularization; (II) patients with stable IHD undergoing coronary artery bypass grafting; (III) controls without coronary obstructions undergoing valve replacement due to aortic stenosis and (IV) controls with healthy coronaries verified by computed tomography. The abundance and distribution of m6A and A-to-I modifications in blood RNA are charted by quantitative and qualitative methods. Selected other modified nucleosides as well as IHD candidate protein and metabolic biomarkers are measured for reference. The results of the IHD-EPITRAN study can be expected to enable identification of epitranscriptomic IHD biomarker candidates and potential drug targets.
KW - 3121 General medicine, internal medicine and other clinical medicine
KW - biomarkers
KW - ischemic heart disease
KW - epitranscriptomics
KW - N6-methyladenosine
KW - m6A
KW - adenosine-to-inosine
KW - A-to-I
KW - RNA modifications
KW - biomarkers
KW - epitranscriptomics
KW - ischemic heart disease
KW - N-6-methyladenosine
KW - adenosine-to-inosine
KW - A-to-I
KW - RNA M(6)A METHYLATION
KW - SINGLE-NUCLEOTIDE-RESOLUTION
KW - BRAIN NATRIURETIC PEPTIDE
KW - STEM-CELL PROLIFERATION
KW - PRE-MESSENGER-RNA
KW - PLATELET MICROPARTICLES
KW - CARDIOVASCULAR-DISEASE
KW - SOLUBLE SUPPRESSION
KW - PROGNOSTIC VALUE
KW - ATHEROSCLEROTIC PLAQUES
KW - 1182 Biochemistry, cell and molecular biology
U2 - 10.3390/ijms22126630
DO - 10.3390/ijms22126630
M3 - Article
VL - 22
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
SN - 1422-0067
IS - 12
M1 - 6630
ER -